Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionEverpar Advisors Llc
Latest Disclosed Ownership919 shares
Latest Disclosed Value $ 410,370
Everpar Advisors Llc reports 15.16% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 21, 2026 - Everpar Advisors Llc filed a 13F-HR form disclosing ownership of 919 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $410,370 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 7, 2026 disclosing 798 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 15.16% during the quarter. The current value of the position is $405,959 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-21 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 919 121 15.16 410 13.57 0.1413
2026-01-07 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 798 45 5.98 362 22.79 0.1342
2025-10-17 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 753 -39 -4.92 295 -16.48 0.1166
2025-07-08 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 792 44 5.88 353 -2.76 0.1602
2025-04-16 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 748 81 12.14 363 35.07 0.1925
2025-01-15 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 667 -26 -3.75 269 -16.77 0.1354
2024-10-07 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 693 -244 -26.04 322 -26.65 0.1667
2024-07-18 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 937 387 70.36 439 91.70 0.2199
2024-04-22 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 550 550 230 0.1398
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.